TY - JOUR T1 - Higher plasma levels of chemokine CCL19 are associated with poor SARS-CoV-2 acute respiratory distress syndrome (ARDS) outcomes JF - medRxiv DO - 10.1101/2020.05.21.20051300 SP - 2020.05.21.20051300 AU - Joseph Balnis AU - Alejandro P. Adam AU - Amit Chopra AU - Hau C. Chieng AU - Paul J. Feustel AU - Katherine A. Overmyer AU - Evgenia Shishkova AU - Joshua J. Coon AU - Harold A. Singer AU - Marc A. Judson AU - Ariel Jaitovich Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/22/2020.05.21.20051300.1.abstract N2 - COVID19 pandemic has so far caused over three hundred thousand deaths worldwide, primarily due to complications from SARS-CoV-2-associated acute respiratory distress syndrome (ARDS). While an ARDS-driven hyperinflammatory phenotype is associated with higher mortality in non-COVID patients, there is little information on how cytokines and chemokines expressions correlate with clinical outcomes in COVID19 patients. We prospectively enrolled a cohort of 41 patients with acute respiratory distress syndrome on mechanical ventilation. Patients’ blood was obtained at enrollment and outcome measures were liberation from mechanical ventilation and hospital-free days. We determined the expression levels of 44 circulating cytokines/chemokines and found 13 of them associated with worse outcomes. After correcting for multiple comparisons/false discovery rate, only one chemokine (CCL19) remained significantly associated with outcomes (p=0.009). Although not described in association with COVID19, this chemokine was previously found elevated in an animal model of SARS-CoV. Moreover, CCL19 seems to be relevant for bronchus-associated lymphoid tissue (BALT) maintenance and for lung immunity to influenza virus. While this finding requires corroboration, CCL19 determination could facilitate early identification of COVID19-ARDS patients at higher risk of death and be novel target for immunotherapy in this setting.Competing Interest StatementThe authors have declared no competing interest.Funding StatementK01-HL130704 (AJ), and by the Collins Family Foundation Endowment (AJ); NIH/NHLBI 5R01HL049426 (HAS); NIH/National Institute of General Medical Sciences Grant 1R01GM124133 (APA); P41 GM108538 (KAO, ES, JJC). No other funding related to this project occurred.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data, including covariables and cytokines are available to the readers https://figshare.com/s/5602c77cd1b7559b1593 ER -